The R&D Empirical Test Of The Chinese Listed Medical Companies

The medical industry is one of the six primary industries in China, as well as the strategic industry which is related to the life and health of the people. Along with the entry into WTO, the Chinese pharmaceutical companies face to the new opportunity and challenge. And the R&D of new technology and new product is the main drive to the pharmacuetical industy and companies. As the one aspect of technology innovation, the R&D has been researched in many papers, but there is few papers which is focus on the R&D of the medical companies. The aim of this thesis is measure the R&D ability of the liested medical companies by comparison and empirical research. As an integareted system, the development of the R&D is influenced by many factors, and it can be measuered by a index system. To medical industy, the R&D has its own characters: high risk, high investment and high revenue, the significant scale economy, the dual layer structure, the importance of the learning of the organization, significant impact of government policies. Based on the R&D theory, we come to the conclusion below according to the the compared and empirical test:1. The R&D ability of the listed medical companies is weak, and the intensity and the sacle is at a low level. The R&D turning out is inefficient, the reture is low, and the innovation contributes little to the companies.2. The internal R&D capability and effiency is low, which results the competition mainly is the price competition. The scale and effiency of R&D cooperation is bad.3. The culture of the Chinese companies makes it difficult to the development of the R&D.